Maynard Um
-
-
-
-
-
-
-
Intellia short interest rises most among biotech stocks in latest period - Baird
-
-
-
-
-
-
-
Dianthus Therapeutics (DNTH) PT Raised to $130 at Clear Street
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Dianthus Therapeutics (DNTH): Phase 3 "results exceeded our expectations"
-
-
-
-
-
-
-
Dianthus Therapeutics (DNTH) PT Raised to $125 at Oppenheimer
-
-
-
-
-
-
-
TD Cowen on Dianthus (DNTH): 'the favorable economics of the deal will not impact prior guidance of cash runway into 2028'
-
-
-
-
-
-
-
Dianthus Therapeutics (DNTH) PT Raised to $100 at Guggenheim
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
-
401,180 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

